GLP-1RAs may increase ischemic optic neuropathy risk
1. In this target trial emulation, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with a small increase in the ...
Tag: DPP-4 inhibitors
GLP-1RAs showed no advantage for basal insulin discontinuation
1. In this target trial emulation, initiating a glucagon-like peptide-1 receptor agonist (GLP-1RA) was not associated with higher rates of ...
Semaglutide may improve cardiovascular outcomes versus empagliflozin in patients with diabetes
1. In this retrospective cohort study, treatment with semaglutide resulted in nominally lower incidence of the composite of death, myocardial ...
#VisualAbstract Glucagon-Like Peptide-1 Receptor Agonists are Protecting in Type 2 Diabetes Mellitus Patients
Click here to read this article in JAMA Internal Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Sodium-glucose cotransporter 2 inhibitor use in patients with type 2 diabetes linked to decreased risk of nephrolithiasis
1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...
Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes associated with reduced atrial fibrillation hospitalization events compared to commonly used comparators
1. This population-based cohort study demonstrated that among older adults with type 2 diabetes, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use was ...
#VisualAbstract: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...
SGLT-2 inhibitors not associated with increased risk for severe UTI
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to ...
